2 • Probe •Vol LXII • No. 4 • Sep–Dec 2023 Preclinical Evidence Diabecon® (TABLET, DS TABLET) Diabecon, a phytopharmaceutical formulation, is recommended for the management of diabetes and associated micro- and macrovascular complications. In newly detected type 2 diabetes, Diabecon, as a monotherapy, significantly reduces fasting plasma glucose, postprandial plasma glucose, and glycated hemoglobin levels. As an adjuvant to insulin or other oral hypoglycemic agents, Diabecon helps in reducing their dosage and prevents the development of tolerance. Effect of Diabecon® on Blood Sugar Level Aim To evaluate the effect of Diabecon on the blood sugar level (BSL) in normal rats and in alloxan-induced diabetic rats Materials and Methods This placebo-controlled study was conducted in male and female Wistar rats aged 2.5 to 3 months, weighing 175 to 250 g. The rats were divided into 2 groups: normoglycemic and alloxan-induced diabetic rats. In normoglycemic rats, 4 procedures were performed, and in alloxan-induced diabetic rats, 2 procedures were performed. Procedures in normoglycemic rats Effect of Diabecononblood sugar level Fifty normoglycemic rats were randomized into 2 groups (25 each). Group 1 (control) received 10 mL/kg body weight of water, and group 2 (test animals) received 2 g/kg body weight of Diabecon fine powder in the form of an aqueous suspension, once a day, orally, for 90 days. Fasting blood samples were collected to determine the blood sugar levels at baseline and after 30 and 90 days of treatment. Interactionwithadrenaline Fasting blood sugar (FBS) level was determined in 8 normoglycemic rats on day 0. Each rat was administered 100 µg of adrenaline subcutaneously, and the BSL was determined at 30, 60, 90, 120, 180, and 240 minutes. After basal blood sugar profiling was done post adrenaline administration, the rats were given Diabecon at a dosage of 2 g/kg, once a day, orally, for 21 days. Again, the FBS level was measured on day 21. Interactionwith tolbutamide In 6 normoglycemic rats, the FBS level was measured on day 0. Each rat received an aqueous suspension of tolbutamide at a dose of 250 mg/kg body weight, orally. The BSL was determined at every 1 hour for 4 hours following administration of tolbutamide. After basal blood sugar profiling was done post tolbutamide administration, the rats were administered an aqueous suspension of Diabecon at a dosage of 2 g/kg body weight, once a day, orally, for 21 days. The FBS level was measured on day 21. Interactionwith insulin The FBS level was measured in 8 normoglycemic rats on day 0. All rats were administered 0.25 IU of insulin intravenously, and the BSL was determined after 30, 60, 90, 120, 180, and 240 minutes. They were then administered Diabecon at a dosage of 2 g/kg body weight, once a day, orally, for 21 days. The FBS level was measured on day 21.
RkJQdWJsaXNoZXIy MjAwNDg=